Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer

Breast Cancer Research and Treatment

Volumn 150, Issue 1, 2015, Pages 71-80

  Wong Brown, Michelle W ^a   Meldrum, Cliff J ^b   Carpenter, Jane E ^c   Clarke, Christine L ^c   Narod, Steven A ^d   Jakubowska, Anna ^e   Rudnicka, Helena ^e   Lubinski, Jan ^e   Scott, Rodney J ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b New South Wales Health Pathology North   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

BRCA1; BRCA2; Genetic testing; Germline mutations; Prevalence; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENOMIC DNA;

ADULT; AGED; ARTICLE; AUSTRALIAN; COHORT ANALYSIS; EXON; FAMILY HISTORY; FEMALE; GENE SEQUENCE; GENETIC CODE; GENETIC SCREENING; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MIDDLE AGED; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OVARY CANCER; POLISH CITIZEN; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; VERY ELDERLY; AUSTRALIA; CANCER GRADING; GENETICS; METASTASIS; OVARIAN NEOPLASMS; PATHOLOGY; PREVALENCE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; AUSTRALIA; EXONS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RISK FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84925486358     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3293-7     Document Type: Article

References (22)

1. Dite GS, Jenkins MA, Southey MC, Hocking JS, Giles GG, McCredie MR, Venter DJ, Hopper JL (2003) Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 95(6):448–457
2. Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7(5):552–556
3. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082–1089
4. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318
5. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819
6. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. BJC 83(10):1301–1308
7. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. JNCI 91(11):943–949
8. Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA et al (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118(11):2787–2795
9. Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D et al (2012) Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat 134(1):353–362
10. Robertson L, Hanson H, Seal S, Warren-Perry M, Hughes D, Howell I, Turnbull C, Houlston R, Shanley S, Butler S et al (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106(6):1234–1238
11. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D et al (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86
12. Phuah SY, Looi LM, Hassan N, Rhodes A, Dean S, Taib NA, Yip CH, Teo SH (2012) Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. Breast Cancer Res 14(6):R142
13. An open access on-line breast cancer mutation data base [http://research.nhgri.nih.gov/bic/]
14. Borg A, Haile RW, Malone KE, Capanu M, Diep A, Torngren T, Teraoka S, Begg CB, Thomas DC, Concannon P et al (2010) Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat 31(3):E1200–E1240
15. Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM (2011) Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 48(8):520–522
16. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM et al (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145–153
17. ®) [www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf]
18. Genetic Testing for Heritable Mutations in the BRCA1 and BRCA2 Genes [https://www.eviq.org.au/]
19. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):115–123
20. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28(3):375–379
21. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 11(348):g226. doi:10.1136/bmj.g226
22. Huzarski T, Byrski T, Gronwald J, Górski B, Domagala P, Cybulski C, Oszurek O, Szwiec M, Gugala K, Stawicka M, Morawiec Z, Mierzwa T, Janiszewska H, Kilar E, Marczyk E, Kozak-Klonowska B, Siolek M, Surdyka D, Wisniowski R, Posmyk M, Sun P, Lubinski J, Narod SA (2013) Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31(26):3191–3196